Communicating the Parameter Uncertainty in the IQWiG Efficiency Frontier to Decision‐Makers [PDF]
Health Economics, 2014 The Institute for Quality and Efficiency in Health Care (IQWiG) developed-in a consultation process with an international expert panel-the efficiency frontier (EF) approach to satisfy a range of legal requirements for economic evaluation in Germany's statutory health insurance system.
Stollenwerk, Björn +7 more
openaire +7 more sources
Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree [PDF]
Health Economics Review, 2019 Background The purpose of this study was to analyse the impact of commissioned addenda by the Federal Joint Committee (FJC) to the HTA body (IQWiG) and their agreement with FJC decisions and to identify potential additional decisive factors of FJC ...
C. M. Dintsios +3 more
doaj +2 more sources
Höchstmöglicher ESMO-Wert vs. kein Zusatzznutzen [PDF]
Monitor VersorgungsforschungIm Titelinterview mit „Monitor Versorgungsforschung“ (02/25) ging Dr. med. Thomas Kaiser, Institutsleiter des IQWiG, kurz auf die Nutzenbewertung des Wirkstoffs Pembrolizumab und des MSD-Arznemittels „Keytruda“ ein (1): Auf die Frage „Wie kommt es, dass ...
Peter Stegmaier
doaj +2 more sources
Imaginary Worlds and Efficiency Frontiers: Should We Abandon the IQWiG Health Technology Assessment Model? [PDF]
INNOVATIONS in Pharmacy, 2017 The contribution of cost-effectiveness analysis to the pricing of pharmaceuticals in Germany is at best marginal and in many, if not most cases, absent.
Paul C Langley
doaj +3 more sources
Cost Recommendation under Uncertainty in IQWiG’s Efficiency Frontier Framework [PDF]
Medical Decision Making, 2016 Background. The National Institute for Quality and Efficiency in Health Care (IQWiG) employs an efficiency frontier (EF) framework to facilitate setting maximum reimbursable prices for new interventions. Probabilistic sensitivity analysis (PSA) is used when yes/no reimbursement decisions are sought based on a fixed threshold. In the IQWiG framework, an
Corro Ramos, Isaac +3 more
openaire +4 more sources
Patients' preferences in periodontal disease treatment elicited alongside an IQWiG benefit assessment: a feasibility study [PDF]
Patient Preference and Adherence, 2018 Vera Vennedey,1 Sonja HM Derman,2 Mickaël Hiligsmann,3 Daniele Civello,1 Anja Schwalm,4 Astrid Seidl,4 Fülöp Scheibler,5 Stephanie Stock,1 Michael J Noack,2 Marion Danner1,5 1Institute for Health Economics and Clinical Epidemiology ...
Vennedey V +9 more
doaj +1 more source
Monitor Versorgungsforschung, 2023 Zur Beurteilung der Wirksamkeit und Sicherheit eines neuen Wirkstoffes ist für die europäische Zulassungsbehörde (European Medicines Agency, EMA) die randomisierte kontrollierte Studie (RCT) der Goldstandard.
Dr. rer. nat. Gerrit Müller +2 more
doaj +1 more source
Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review
BMC Pregnancy and Childbirth, 2020 Background All non-sensitized Rhesus D (RhD)-negative pregnant women in Germany receive antenatal anti-D prophylaxis without knowledge of fetal RhD status.
Britta Runkel +5 more
doaj +1 more source
BMC Rheumatology, 2022 Background Some composite measures for determining the treatment effects of disease-modifying antirheumatic drugs on remission and low disease activity (LDA) in rheumatoid arthritis (RA) may produce misleading results if they include an acute phase ...
Kirsten Janke +5 more
doaj +1 more source
Meta-analysis data extracted from IQWiG publications [PDF]
, 2018 This data set contains data on 40 meta-analyses extracted from publications by the German Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen; IQWiG).
Röver, Christian +2 more
core +1 more source